Richard Klar

1.3k total citations · 1 hit paper
22 papers, 918 citations indexed

About

Richard Klar is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Richard Klar has authored 22 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Richard Klar's work include Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (8 papers) and CAR-T cell therapy research (7 papers). Richard Klar is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (8 papers) and CAR-T cell therapy research (7 papers). Richard Klar collaborates with scholars based in Germany, United States and Switzerland. Richard Klar's co-authors include Angela M. Krackhardt, Christian Peschel, Dirk H. Busch, Stefan Audehm, Melanie Straub, Julia Slotta‐Huspenina, Thomas Engleitner, Jürgen Cox, Pavel Sinitcyn and Matthias Mann and has published in prestigious journals such as Nature Communications, The Journal of Immunology and Cancer Research.

In The Last Decade

Richard Klar

22 papers receiving 907 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

2016 469 citations Michal Bassani‐Sternberg, Eva Bräunlein et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Klar Germany	13	541	493	429	151	62	22	918
L Deneux France	11	316 0.6×	378 0.8×	344 0.8×	130 0.9×	17 0.3×	17	838
Christina R. Hartigan United States	11	467 0.9×	782 1.6×	235 0.5×	133 0.9×	17 0.3×	16	1.1k
Kayluz Frias Boligan Switzerland	12	508 0.9×	515 1.0×	161 0.4×	120 0.8×	52 0.8×	21	789
Jan Žaloudík Czechia	20	479 0.9×	582 1.2×	523 1.2×	289 1.9×	45 0.7×	62	1.2k
Claudia Gordon United States	9	241 0.4×	388 0.8×	127 0.3×	131 0.9×	63 1.0×	13	598
Seema Chugh United States	15	240 0.4×	615 1.2×	307 0.7×	47 0.3×	76 1.2×	23	811
Oriana E. Hawkins United States	16	326 0.6×	277 0.6×	290 0.7×	39 0.3×	76 1.2×	19	687
Christie Fanton United States	11	267 0.5×	198 0.4×	288 0.7×	38 0.3×	20 0.3×	26	587
Bangzheng Chen United States	6	155 0.3×	584 1.2×	320 0.7×	28 0.2×	26 0.4×	8	900
Yu. V. Cheburkin Russia	8	386 0.7×	371 0.8×	170 0.4×	25 0.2×	44 0.7×	21	779

Countries citing papers authored by Richard Klar

Since Specialization

Citations

This map shows the geographic impact of Richard Klar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Klar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Klar more than expected).

Fields of papers citing papers by Richard Klar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Klar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Klar. The network helps show where Richard Klar may publish in the future.

Co-authorship network of co-authors of Richard Klar

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Klar. A scholar is included among the top collaborators of Richard Klar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Klar. Richard Klar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michel, Sven, et al.. (2024). Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides. Nucleic Acid Therapeutics. 34(5). 257–271. 2 indexed citations

Kaufmann, Benedikt, Laela M. Booshehri, Janset Onyuru, et al.. (2023). Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. The Journal of Immunology. 211(2). 287–294. 6 indexed citations

Cianciaruso, Chiara, Ruben Bill, Marcel P. Trefny, et al.. (2023). Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity. Journal for ImmunoTherapy of Cancer. 11(5). e006714–e006714. 14 indexed citations

Michel, Sven, Richard Klar, & Frank Jaschinski. (2021). Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing. Nucleic Acid Therapeutics. 31(6). 427–435. 1 indexed citations

Shahzad, Khurrum, Sameen Fatima, Moh’d Mohanad Al‐Dabet, et al.. (2021). CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease. Journal of the American Society of Nephrology. 32(12). 3066–3079. 21 indexed citations

Shen, Minhong, Shanshan Xie, Michelle Rowicki, et al.. (2020). Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Research. 81(4). 1014–1025. 37 indexed citations

Festag, Julia, et al.. (2020). Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation. Molecular Therapy — Nucleic Acids. 21. 656–669. 12 indexed citations

Michel, Sven, et al.. (2020). Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines. Molecular Diagnosis & Therapy. 25(1). 77–85. 18 indexed citations

Cao, Yu, Jimena Trillo-Tinoco, Rosa A. Sierra, et al.. (2019). ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. 10(1). 1280–1280. 111 indexed citations

10.

Klar, Richard, et al.. (2019). A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer Immunology Immunotherapy. 69(1). 57–67. 6 indexed citations

11.

Cao, Yu, Jimena Trillo-Tinoco, Rosa A. Sierra, et al.. (2019). Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. 10(1). 3680–3680. 5 indexed citations

12.

Audehm, Stefan, Matteo Pecoraro, Eva Bräunlein, et al.. (2019). Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer. Frontiers in Immunology. 10. 1485–1485. 7 indexed citations

13.

Dietzel, Erik, Sven Michel, Markus Helfer, et al.. (2019). Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro. Molecular Therapy — Nucleic Acids. 16. 686–697. 11 indexed citations

14.

Kashyap, Abhishek S., Richard Klar, Sandra M. Kallert, et al.. (2019). Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. Journal for ImmunoTherapy of Cancer. 7(1). 67–67. 51 indexed citations

15.

Mall, Sabine, Katja Steiger, Sybille Reder, et al.. (2017). In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET. Theranostics. 7(9). 2402–2416. 29 indexed citations

16.

Mall, Sabine, Richard Klar, Katja Steiger, et al.. (2016). Immuno-PET Imaging of Engineered Human T Cells in Tumors. Cancer Research. 76(14). 4113–4123. 44 indexed citations

17.

Bassani‐Sternberg, Michal, Eva Bräunlein, Richard Klar, et al.. (2016). Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nature Communications. 7(1). 13404–13404. 469 indexed citations breakdown →

18.

Grünewald, Thomas G. P., Richard Klar, Dirk Wohlleber, et al.. (2016). Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. OncoImmunology. 5(6). e1175795–e1175795. 23 indexed citations

19.

Klar, Richard, Sebastian Johannes Schober, Juliane Merl, et al.. (2014). Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Leukemia. 28(12). 2355–2366. 19 indexed citations

20.

Weigand, Luise, Sabine Mall, Richard Klar, et al.. (2012). Isolation of human MHC class II‐restricted T cell receptors from the autologous T‐cell repertoire with potent anti‐leukaemic reactivity. Immunology. 137(3). 226–238. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact